CardiaTec is applying artificial intelligence on large-scale human multi-omics data to develop the next generation of cardiovascular disease drug targets.

Laidlaw Scholars Ventures

O2h Ventures

APEX Ventures

Crista Galli Ventures

University of Cambridge Enterprise

CardiaTec Biosciences

🌟 Advisor Spotlight: Dr. Christopher Miller 🌟

We are thrilled to introduce Dr. Christopher Miller, a valued member of our Scientific Advisory Board. Chris brings a distinguished career spanning 30 years in applied genomics, functional genomics, and multi-omics, having contributed significantly at Bristol Myers Squibb, AbbVie, Pfizer, and GSK. Throughout his career, Chris has played a pivotal role in drug target identification, target validation, drug discovery, and development, translating results from human genetics into impactful drug discovery programs.

Welcome on board once again! 🚀

🌟 Spotlight 🌟

Thrilled to see our COO & Co-Founder, Thelma Zablocki, at the InspiringFifty Women In Tech Breakfast organised by EQL:HER & Founders Forum Group, alongside Meta. 🎉

#WomenInTech #Leadership #AIdrugdiscovery #EQLHER #FoundersForumGroup #Meta 

Exciting news! Our founders will be at the LSX Conference on November 13th. This is a chance to connect and explore CardiaTec Biosciences's ambitions and future prospects 🚀 

Link: https://lnkd.in/eE_QBbD 

Cardiatec is a medical technology company specializing in developing innovative solutions for cardiovascular health monitoring and management.

AI:CARDIATEC

Cardiatec

Filings Not Available